Myomo (MYO) Research & Development (2016 - 2025)
Myomo (MYO) posted Research & Development of $5.3 million for Q3 2025, little changed on a QoQ basis from $5.2 million in Q2 2025, and up 320.72% year-over-year from $1.2 million in Q3 2024.
Myomo (MYO) Research & Development (2016 - 2025) Analysis & Trends
Myomo's Research & Development history runs 10 years deep, the most recent figure standing at $5.3 million for Q3 2025.
- Quarterly Research & Development rose 320.72% year-over-year to $5.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $16.0 million (up 2000.01% YoY) and the FY2024 annual result came in at $12.2 million, up 364.14% from the prior year.
- Research & Development was $5.3 million for Q3 2025 at Myomo, roughly flat from $5.2 million in the prior quarter.
- Across five years, Research & Development topped out at $5.3 million in Q3 2025 and bottomed at -$4.1 million in Q4 2023.
- A 5-year average of $1.3 million and a median of $787628.0 in 2021 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development sank 911.15% — and 2025, when it soared 419.63%.
- Myomo's Research & Development stood at $787628.0 in 2021, then slumped by 36.56% to $499674.0 in 2022, then sank by 911.15% to -$4.1 million in 2023, then soared by 191.21% to $3.7 million in 2024, then jumped by 42.13% to $5.3 million in 2025.
- Business Quant data shows MYO's Research & Development at $5.3 million in Q3 2025, $5.2 million in Q2 2025, and $1.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 767.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 413.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 516.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 263.30 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 145.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -461.27 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 345.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Myomo | 39.24 Mn | 20.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.25 Mn |
| Jun 30, 2025 | 5.23 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 3.70 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 956,215.00 |
| Dec 31, 2023 | -4.05 Mn |
| Sep 30, 2023 | 2.39 Mn |
| Jun 30, 2023 | 564,235.00 |
| Mar 31, 2023 | 2.03 Mn |
| Dec 31, 2022 | 499,674.00 |
| Sep 30, 2022 | 690,407.00 |
| Jun 30, 2022 | 632,872.00 |
| Mar 31, 2022 | 659,536.00 |
| Dec 31, 2021 | 787,628.00 |
| Sep 30, 2021 | 641,228.00 |
| Jun 30, 2021 | 600,116.00 |
| Mar 31, 2021 | 525,967.00 |
| Dec 31, 2020 | 418,758.00 |